这种新方法的明显安全性也使得研究CAR-NK细胞治疗实体瘤和自身免疫性疾病的潜力具有吸引力。 参考文献 Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial...
Gilead’s Kite invests $285M more, expands Arcellx CAR T deal to include lymphoma Nov. 15, 2023 No Comments If there had been any lingering market concerns following the temporary partial clinical hold earlier this year for Arcellx Inc.’s multiple myeloma CAR T-cell therapy, CART-ddBCMA,...
阿基仑赛的适应证包括弥漫性大B细胞淋巴瘤非特指型(diffuse large B-cell lymphoma,DLBCL)、滤泡性淋巴瘤(follicular lymphoma,FL)转化的大B细胞淋巴瘤(large B-cell lymphoma,LBCL)、原发性纵隔大B 细胞淋巴瘤(primary mediastinal large B-cell lymphoma,PMBCL)和高级别B细胞淋巴瘤(high grade B cell lymphoma,H...
B cell lymphoma and multiple myeloma1,2,3,4, but the efficacy of CAR T cell therapy in solid tumours has been limited5. This is owing to a number of factors, including the immunosuppressive tumour microenvironment that gives rise to poorly...
[4]Wang L,et al.Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial[J]. Blood cancer journal, 2024, 14(1): 130. https://www.natu...
CAR-T疗法在实体瘤疗效不佳暴露出一些该疗法局限性: 难以治疗异质性较强肿瘤; CAR-T细胞很难浸润到实体瘤内部; CAR-T细胞在体内耗竭失去控瘤功能; CAR-T疗法会带来细胞因子风暴、神经毒性等毒副作用和不良反应。 四 CAR-T细胞制备流程和质控 CAR-T细胞制剂的制备包括质粒制备、病毒制备、样本采集、接收、处理、细...
During an OncLive Peer Exchange®, a panel of lymphoma experts discussed several novel agents for R/R DLBCL, some of which have been recently approved. They examined the clinical trial data, discussed how these agents compare with CAR T-cell therapy, and provided insights on how they might ...
ESO-T01是一种第三代复制缺陷型自失活慢病毒载体,也是一种免疫屏蔽慢病毒载体,可在体内将T淋巴细胞特异性地重新编程为高效的BCMACAR-T细胞,具备免疫屏蔽性,并且对吞噬作用有抗性。作为首个进入人体临床试验并给药的体内BCMACAR-T候...
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial Article 12 January 2024 Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial Article Open...
3.Raut LS, Chakrabarti PP. Management of relapsed-refractory diffuse large B cell lymphoma. South ...